Radioimmunotherapy: Is There Any Future Role?

Radioimmunotherapy targeting CD20 with 90 yttrium-ibritumomab tiuxetan (90 Y-IT) is approved for the treatment of relapsed and refractory follicular lymphoma patients. Radioimmunotherapy has also been explored as a component of the chemotherapy administered in preparation to autologous stem cell transplantation. The use of 90 Y-IT has significantly declined in the last decade after an initial excitement, mainly because of logistic and commercial reasons. 117-lutetium (117 Lu) lilotomab satetraxetan (117 Lu-LS) is an anti-CD37 murine monoclonal antibody (lilotomab) linking to the beta-emitter 117 Lu was granted fast track designation for relapsed and refractory follicular lymphoma by the Food and Drug Administration in June 2018 and for patients with marginal zone lymphoma who have failed at least two prior therapies in June 2020. Interest in agents targeting CD37 may help invigorate interest in the use of radioimmunoconjugates.